-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Earnings Call Summary | Dare Bioscience(DARE.US) Q4 2023 Earnings Conference
Earnings Call Summary | Dare Bioscience(DARE.US) Q4 2023 Earnings Conference
The following is a summary of the Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript:
Financial Performance:
Daré Bioscience recorded total revenue of about $2.8 million in 2023, anchored by payments from commercial collaborator Organon.
The company's G&A expenses were roughly $12.1 million, with R&D expenses reaching about $21.5 million.
The company reported a net loss of $30.1 million for 2023, leaving $10.5 million in cash and cash equivalents.
Through non-dilutive grant funding, a direct offering, and a royalty-backed investment, Daré Bioscience generated about $24 million.
Business Progress:
Significant progress was observed in the development of women's health pharmaceutical products, with products progressing well at all stages of the pipeline.
The year saw 15 FDA interactions for six product indications and the completion of Phase 2b studies for the Sildenafil Cream.
Presently, Phase 3 studies for Ovaprene, a hormone-free monthly contraceptive candidate, have begun.
Commercially, the product XACIATO for bacterial vaginosis treatment became widely available by prescription in early 2024, and the company is expecting royalty revenue from Organon.
In 2024, Daré is targeting reduced G&A expenses to about $10m and anticipates lower R&D expenses due to more focused clinical trials.
The company also revealed its plans to continue potential financing opportunities, with milestones including FDA discussions on Phase 3 trial designs and updates on key assets XACIATO, Ovaprene, and Sildenafil Cream.
Preparations are ongoing for IND applications for the product HRT1 and the Phase 2 study for the product VVA1, contingent on securing additional capital.
More details: Dare Bioscience IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
The following is a summary of the Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript:
以下是达瑞生物科学公司(DARE)2023年第四季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
Daré Bioscience recorded total revenue of about $2.8 million in 2023, anchored by payments from commercial collaborator Organon.
The company's G&A expenses were roughly $12.1 million, with R&D expenses reaching about $21.5 million.
The company reported a net loss of $30.1 million for 2023, leaving $10.5 million in cash and cash equivalents.
Through non-dilutive grant funding, a direct offering, and a royalty-backed investment, Daré Bioscience generated about $24 million.
达瑞生物科学在2023年录得的总收入约为280万美元,这主要来自商业合作者Organon的付款。
该公司的并购费用约为1,210万美元,研发费用约为2150万美元。
该公司报告称,2023年净亏损3,010万美元,剩下1,050万美元的现金和现金等价物。
通过非稀释性拨款、直接发行和特许权使用费支持的投资,达瑞生物科学产生了约2400万美元的收入。
Business Progress:
业务进展:
Significant progress was observed in the development of women's health pharmaceutical products, with products progressing well at all stages of the pipeline.
The year saw 15 FDA interactions for six product indications and the completion of Phase 2b studies for the Sildenafil Cream.
Presently, Phase 3 studies for Ovaprene, a hormone-free monthly contraceptive candidate, have begun.
Commercially, the product XACIATO for bacterial vaginosis treatment became widely available by prescription in early 2024, and the company is expecting royalty revenue from Organon.
In 2024, Daré is targeting reduced G&A expenses to about $10m and anticipates lower R&D expenses due to more focused clinical trials.
The company also revealed its plans to continue potential financing opportunities, with milestones including FDA discussions on Phase 3 trial designs and updates on key assets XACIATO, Ovaprene, and Sildenafil Cream.
Preparations are ongoing for IND applications for the product HRT1 and the Phase 2 study for the product VVA1, contingent on securing additional capital.
女性健康药品的开发取得了重大进展,产品在开发的各个阶段都进展良好。
这一年,六种产品适应症共进行了15次FDA互动,并完成了西地那非乳膏的2b期研究。
目前,Ovaprene(一种无激素的月用避孕药候选药物)的三期研究已经开始。
商业上,用于细菌性阴道病治疗的产品XACIATO于2024年初通过处方广泛上市,该公司预计Organon将获得特许权使用费收入。
2024年,达雷的目标是将并购费用减少至约1000万美元,并预计由于临床试验更加集中,研发费用将降低。
该公司还透露了继续提供潜在融资机会的计划,其里程碑包括美国食品药品管理局关于第三阶段试验设计的讨论以及关键资产XACIATO、Ovaprene和西地那非霜的最新情况。
HRT1产品的IND申请和VVA1产品的第二阶段研究的准备工作正在进行中,前提是获得额外资金。
More details: Dare Bioscience IR
更多详情: Dare 生物科学 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧